It reduces gastrointestinal motility, impeding the emptying of the stomacha function that keeps the patient feeling fuller for longer
Keep out of reach of children under 18
Central GLP-1 activation may be combined with GLP-2 and/or OXM activation to form a potential pharmacological tool to reduce meal intake and possibly increase energy consumption (25, 27)
In the UK, it is illegal to purchase retatrutide for cosmetic use
Less common side effects may include fatigue, headaches, dizziness, or injection site reactions
This knowledge helps predict patient responses, identify research gaps, and guide the development of innovative therapeutic strategies